Hyderabad|India|September'2010: Dr.Ashwini Nangia, Professor of Chemistry at University of Hyderabad along with his team comprising a former School of Chemistry at UoH, Ms. Monika Verma, CEO, Avance Phytopharmaceuticals, Ahmedabad and Dr. Shiv Prakash, MD, Synchron Research, has been adjudged the best team among three short-listed teams from Universities and Research institutes across India at a UK-India Biotech-Pharma Business Plan at the Nottingham University, UK.

This recognition carries prize money of Rs. 15 lacs given by the Department of Science and Technology, Government of India and further financial and expert support from the UK firms and researchers.

This honour testifies Prof. Nangia’s knowledge of innovation to market ideas. The team has won the distinction for the project titled ‘Chalk2Salt’ in which insoluble drug molecules like Chalk dust is transformed into high solubility solid forms as table salt.

BioPharm 2020, the UK-India Biotech Pharma Business Plan brings together researchers, academicians and industrialists and is aimed to build bridges between Biotechnology researchers and entrepreneurs in the UK and India and help them develop their biotechnology and pharmaceutical business ideas into commercially viable ventures.

Prof. Nangia, did his Ph.D from Yale University, USA and his research interests include Supramolecular Synthesis, Host-guest Chemistry, Polymorphism and Cocrystals.